After a long period of time, cathepsin K inhibitors are now re-assessed in osteoclast-mediated bone resorption (60) and re-evaluated for treatment of bone disease caused by metastasizing (breast) carcinoma cells (61, 62). This evidence concerns the gene CTSK and breast carcinoma.